TNFSF13B and IgA glomerulonephritis: The superior performance of sibeprenlimab, an anti-APRIL monoclonal antibody, with 39.0% proteinuria reduction and no increase in serious adverse events, validates the previous concepts from basic science research implicating BAFF/APRIL pathways in IgA nephropathy pathogenesis and demarcates these agents as possible first-line therapeutics for certain selected patients in the future [44,45,46].